Anzeige
Mehr »
Login
Freitag, 26.02.2021 Börsentäglich über 12.000 News von 656 internationalen Medien
Adhoc-Meldung: Eine ganz große Überraschung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9YT ISIN: ES0169501022 Ticker-Symbol: PMRA 
Stuttgart
26.02.21
08:03 Uhr
109,00 Euro
-2,00
-1,80 %
Branche
Biotechnologie
Aktienmarkt
IBEX-35
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
108,00113,0008:00
109,00113,0008:00

Aktuelle News zur PHARMAMAR Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.02.Pharma Mar to trial Aplidin on hospitalised UK COVID patients20
17.02.PHARMA MAR, S.A.: The Company announces that it has obtained Medicines and Healthcare products Regulatory Agency (MHRA) approval for UK patients to participate in the Phase III NEPTUNO clinical trial.6
PHARMAMAR Aktie jetzt für 0€ handeln
01.02.PharmaMar shares jump after solid lung cancer drug results22
01.02.PHARMA MAR, S.A.: The Company sends a press release regarding the presentation of new data on Zepzelca (lurbinectedin) in combination with irinotecan during the IASLC 2020 World Lung Cancer Conference.18
28.01.PharmaMar's cancer drug has 'potent preclinical efficacy' against COVID-1918
26.01.UPDATE 2-PharmaMar soars 21% after journal Science confirms drug's efficacy against COVID43
26.01.UPDATE 1-PharmaMar says paper in journal Science confirms drug's efficacy18
26.01.Science Magazine confirms efficacy of PharmaMar's Plitidepsin against COVID-1921
26.01.PHARMA MAR, S.A.: The Company reports that the publication titled "Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A" has been published in Science.14
07.01.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between 30/09/2020 and 31/12/202016
11.12.20PHARMA MAR, S.A.: The Company informs of the substitution of the individual representative of the director Rosp Corunna Participaciones Empresariales, S.L., its resignation as member of the Audit Committee and the modification of the Board of Directors' R14
03.12.20Jazz Pharma, PharmaMar Report Results Of Phase 3 Study Evaluating Zepzelca Plus Doxorubicin44
03.12.20PHARMA MAR, S.A.: The company announces results of the ATLANTIS phase III study with lurbinectedin29
03.12.20Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line1.794DUBLIN, Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized...
► Artikel lesen
24.11.20PHARMA MAR, S.A.: The Company reports that its subsidiary Genomica, S.A.U., has obtained a CE marking for a new multiviral PCR test for COVID-19, Influenza A and B and Respiratory Syncytial Virus (RSV) diagnostic.16
23.11.20PHARMA MAR, S.A.: Registration within the Madrid Mercantile Registry of the resolution to reduce capital by means of the redemption of own shares.12
10.11.20PHARMA MAR, S.A.: The company sends communication of inside information at the request of the CNMV28
03.11.20Pharma Mar posts 131 million euro 9-mo net profit thanks to Jazz Pharma agreement23
03.11.20PHARMA MAR, S.A.: The Company sends press release regarding the Q3 2020 results6
28.10.20PHARMA MAR, S.A.: Implementation of the reduction of share capital by means of the redemption of own shares approved by the General Shareholders' Meeting of 18 June 2020 under item number three of the agenda.6
Seite:  Weiter >>
46 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3